Apogee Therapeutics Inc
APGE
Company Profile
Business description
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Contact
221 Crescent Street
Building 17, Suite 102b
WalthamMA02453
USAT: +1 650 394-5230
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
196
Stocks News & Analysis
stocks
Nvidia: Collaboration with Intel might bring some goodwill with the US
We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.
stocks
What now for Santos after takeover offer collapses?
Our Fair Value estimate once again reflects the stand-alone business and its growth potential.
stocks
Morningstar initiates coverage on small cap ASX REIT
Coverage of ASX listed REIT as investor interest in property continues to grow.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,085.20 | 37.30 | -0.41% |
| CAC 40 | 7,854.61 | 36.39 | 0.47% |
| DAX 40 | 23,674.53 | 315.35 | 1.35% |
| Dow JONES (US) | 46,142.42 | 124.10 | 0.27% |
| FTSE 100 | 9,228.11 | 32.45 | 0.35% |
| HKSE | 26,576.59 | 138.08 | 0.52% |
| NASDAQ | 22,470.72 | 209.40 | 0.94% |
| Nikkei 225 | 44,752.32 | 149.95 | -0.33% |
| NZX 50 Index | 13,179.13 | 55.76 | -0.42% |
| S&P 500 | 6,631.96 | 31.61 | 0.48% |
| S&P/ASX 200 | 8,797.60 | 50.90 | -0.58% |
| SSE Composite Index | 3,830.65 | 1.00 | -0.03% |